Shorter radiation course for cervical cancer tested in new trial

NCT ID NCT07439497

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a shorter course of radiation therapy (hypofractionated IMRT) given alongside chemotherapy (cisplatin) for cervical cancer. The goal is to see if this approach can reduce the overall treatment time from the usual 7-8 weeks while still controlling the tumor effectively. The study will enroll 34 patients with stage IIB-IVA cervical cancer and measure tumor shrinkage, recurrence rates, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (hypofractionated intensity-modulated radiation therapy) and chemotherapy (cisplatin)
What this could lead to: If successful, this could offer a shorter, more convenient radiation schedule for cervical cancer patients without compromising tumor control.
What could go wrong: This is a small, early-phase trial with only 34 participants. The shorter schedule may not be as effective or could cause more side effects than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam-gu, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.